NCT02611960View on ClinicalTrials.gov

Study of Pembrolizumab (MK-3475) in Platinum Pre-treated Recurrent/Metastatic Nasopharyngeal Cancer (MK-3475-122/KEYNOTE-122)

PHASE3CompletedINTERVENTIONAL
Enrollment

233

Participants

Timeline

Start Date

April 18, 2016

Primary Completion Date

November 30, 2020

Study Completion Date

September 30, 2022

Conditions
Nasopharyngeal Neoplasms
Interventions
BIOLOGICAL

Pembrolizumab

IV infusion

DRUG

Capecitabine

oral tablet

DRUG

Gemcitabine

IV infusion

DRUG

Docetaxel

IV infusion

All Listed Sponsors
lead

Merck Sharp & Dohme LLC

INDUSTRY

NCT02611960 - Study of Pembrolizumab (MK-3475) in Platinum Pre-treated Recurrent/Metastatic Nasopharyngeal Cancer (MK-3475-122/KEYNOTE-122) | Biotech Hunter | Biotech Hunter